Inhibition of PCIF1 improves the sensitivity of CRC tumors to PD-1 therapy by controlling PCIF1-mediated FOS-TGF- and Stat1/Ifitm3-IFN axis. This evidence concerns the gene PCIF1 and colorectal carcinoma.